Underlying growth is positive, but emerging biotech recovery remains delayed and is the primary fiscal 2027 swing factor.
| Quarter | Q3 FY26 |
|---|---|
| Length | 58 minutes |
| EPS | $0.48 |
| EPS consensus | $0.48 |
| Revenue | $311.4M |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q2 FY26 · Q1 FY26 · Q4 FY25 · Q3 FY25
Read the full Q3 FY26 earnings call transcript
All TECH earnings · Back to TECH overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.